Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
20–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Japanese participants with WHO grade III or IV malignant glioma
70 or above on Karnofsky Performance Status in Arm A of Phase 1 portion and Phase 2 portion
80 or above on Karnofsky Performance Status in Arm B and Arm C of Phase 1 portion
Adequate bone marrow function
Recurrent malignant glioma per RANO criteria in Arm A of Phase 1 portion and Phase 2 portion
Histologically proven newly diagnosed malignant glioma in Arm B and Arm C of Phase 1 portion
Participants must have confirmed EGFR amplification by central lab in Phase 2 portion
You may not be if
Anti-cancer treatment 28 days prior to study Day 1 for Arm A of Phase 1 portion and Phase 2 portion (except temozolomide therapy for newly diagnosed treatment for Phase 2 portion)
Anti-cancer treatment prior to study Day 1 for Arm B and Arm C of Phase 1 portion
Participant has received prior treatment with bevacizumabor, EGFR therapy in Arm A of Phase 1 portion and Phase 2 portion, or for recurrent glioblastoma in Phase 2 portion
Participant has a history of major immunologic reaction to any Immunoglobulin G containing agents or component of ABT-414.
